免疫介导的血栓性血小板减少性紫癜的强化利妥昔单抗方案可避免对标准利妥昔单抗治疗无反应。 - Suppr | 超能文献

相似文献

1

Intensive rituximab regimen in immune-mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment.免疫介导的血栓性血小板减少性紫癜的强化利妥昔单抗方案可避免对标准利妥昔单抗治疗无反应。

Br J Haematol. 2021 Jan;192(1):e21-e25. doi: 10.1111/bjh.17170. Epub 2020 Nov 20.

2

Ofatumumab for TTP in a Patient with Anaphylaxis Associated with Rituximab.奥法木单抗治疗与利妥昔单抗相关过敏反应的血栓性血小板减少性紫癜患者

N Engl J Med. 2018 Jan 4;378(1):92-93. doi: 10.1056/nejmc1714146.

3

Thrombotic Thrombocytopenic Purpura Treated with Rituximab Associated with Primary Sjögren's Syndrome and Primary Hypothyroidism.利妥昔单抗治疗血栓性血小板减少性紫癜合并原发性干燥综合征和原发性甲状腺功能减退症

Intern Med. 2020 Mar 1;59(5):715-719. doi: 10.2169/internalmedicine.3722-19. Epub 2019 Nov 8.

4

Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura.利妥昔单抗可降低血栓性血小板减少性紫癜患者的复发风险。

Blood. 2016 Jun 16;127(24):3092-4. doi: 10.1182/blood-2016-03-703827. Epub 2016 Apr 8.

5

Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura.预防性利妥昔单抗可预防免疫介导性血栓性血小板减少性紫癜的长期复发。

Blood. 2018 Nov 15;132(20):2143-2153. doi: 10.1182/blood-2018-04-840090. Epub 2018 Sep 10.

6

Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura.获得性血栓性血小板减少性紫癜患者循环中ADAMTS13特异性免疫复合物的持续存在。

Haematologica. 2014 Apr;99(4):779-87. doi: 10.3324/haematol.2013.094151. Epub 2013 Nov 15.

7

Rituximab for thrombotic thrombocytopenic purpura.

Isr Med Assoc J. 2011 Jul;13(7):436-7.

8

Management of thrombotic thrombocytopenic purpura.血栓性血小板减少性紫癜的管理

Transfus Clin Biol. 2017 Sep;24(3):148-153. doi: 10.1016/j.tracli.2017.05.015. Epub 2017 Jun 20.

9

Successful use of rituximab in a patient with refractory thrombotic thrombocytopaenic purpura complicated by polymyositis.

Scand J Rheumatol. 2017 Mar;46(2):163-165. doi: 10.1080/03009742.2016.1181204. Epub 2016 Jun 16.

10

Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab.伴慢性髓系单核细胞白血病的 Coombs 阳性难治性获得性血栓性血小板减少性紫癜患者经利妥昔单抗治疗后成功缓解。

Acta Clin Belg. 2020 Oct;75(5):357-361. doi: 10.1080/17843286.2019.1608395. Epub 2019 Apr 22.

引用本文的文献

1

Anti-ADAMTS13 Antibodies Trajectory is Associated With ADAMTS13 Recovery in Immune-Mediated TTP.抗ADAMTS13抗体轨迹与免疫介导的血栓性血小板减少性紫癜中ADAMTS13的恢复相关。

Am J Hematol. 2025 Oct;100(10):1736-1746. doi: 10.1002/ajh.70005. Epub 2025 Jul 15.

2

How we manage immune-mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance.利妥昔单抗治疗失败或不耐受后，我们如何管理免疫介导的血栓性血小板减少性紫癜。

Br J Haematol. 2025 Jun;206(6):1560-1570. doi: 10.1111/bjh.20101. Epub 2025 Apr 24.

3

Immune thrombotic thrombocytopenic purpura: Spotlight on long-term outcomes and survivorship.